Lab Report
Scientific Report 2010 Vousden (143.37 kB)
Key Publications
Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327-41.
Carter S, Bischof O, Dejean, Vousden KH. (2007). C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biology 9, 428-435.
Uldrijan S, Pannekoek WJ, Vousden KH. (2007). An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO Journal 26, 102-112.
Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-20.
Yang Y, Ludwig RL, Jensen JP, Pierre S, Medaglia MV, Davydov I, Safiran YJ, Oberi P, Kenten J, Phillips AC, Weissman AM, Vousden KH (2005). Small molecule inhibitors of HDM3 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7, 547-59.
Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH (2003). Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-8.
Biography
Education and qualifications
1982: PhD, University of London, Supervisor Lorna Casselton
1978: BSc, Genetics and Microbiology (First Class Honours), University of London
Appointments
2002-present: Director, Beatson Institute for Cancer Research, Glasgow
1999-2002: Laboratory Chief, NCI-FCRDC, USA
1998-1999: Interim Director, ABL Basic Research Programme, USA
1995-1998: Laboratory Director, ABL Basic Research Programme, USA
1987-1995: Group Head, Ludwig Institute for Cancer Research, London
1985-1987: Visiting Fellow with Doug Lowy, NCI, USA
1981-1985: Postdoctoral Fellow with Chris Marshall, ICR, London
Honours and awards
The Sir Frederick Gowland Hopkins Memorial Medal Lecture, 2008
The Mike Price Lecture, 2008
Honorary DSc, University of Strathclyde, 2008
Fellow of the Academy of Medical Sciences, 2006
Honorary DSc, University of London, 2006
Fellow of the Royal Society of Edinburgh, 2004
Member of EMBO, 2004
Tom Connors Award Lecture, BACR, 2003
Wellcome Trust Lecture, BSCB, 2003
Fellow of the Royal Society, 2003
NIH Merit Award for Major Contributions to Research, 2001
Tenovus Gold Medal for Contributions to the Field of Gene Expression, 1998
Recent Publications
2011
Maddocks OD, Vousden KH (2011). Metabolic regulation by p53. J Mol Med. 89, 237-45. Erratum in: J Mol Med. 89, 531.
Muller PA, Vousden KH, Norman JC (2011). p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 192, 209-18.
2010
Vigneron AM, Ludwig RL, Vousden KH (2010).
Cytoplasmic ASPP1 inhibits apoptosis through the
control of YAP. Genes Dev. 24, 2430-9
.
Croft DR, Crighton D, Samuel MS, Lourenco FC, Munro J, Wood J, Bensaad K, Vousden
KH, Sansom OJ, Ryan KM, Olson MF (2010).
p53-mediated transcription and activation of the
actin cytoskeleton regulatory RhoC to LIMK2
signaling pathway promotes cell survival. Cell Res. 21, 666-82.
O'Prey J, Crighton D, Martin AG, Vousden KH,
Fearnhead HO, Ryan KM (2010).
p53-mediated induction of Noxa and p53AIP1
requires NFkappaB. Cell Cycle 9, 947-52.
Cheung EC, Vousden KH (2010).
The role of p53 in glucose metabolism. Curr Opin
Cell Biol. 22, 186-91.
Hock A, Vousden KH (2010).
Regulation of the p53 pathway by ubiquitin and
related proteins. Int J Biochem Cell Biol. 42,
1618-21.
Vigneron A, Vousden KH (2010).
p53 and Mdm2: an auld alliance. Cell Cycle 9,
865-6.
Vigneron A, Vousden KH (2010).
p53, ROS and senescence in the control of aging.
Aging 2, 471-4.
Vousden KH (2010).
Alternative fuel - another role for p53 in the
regulation of metabolism. Proc Natl Acad Sci USA
107, 7117-8.
2009
Bensaad K, Cheung EC, Vousden KH (2009). Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J. 28, 3015-26.
Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327-41.
Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH (2009). PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 16, 1135-45.
Carter S, Vousden KH (2009). Modifications of p53: competing for the lysines. Curr Opin Genet Dev. 19, 18-24.
Galluzzi L
et al. (2009). Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 16, 1093-107.
Gottlieb E and Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect. a001040, published online 2 Dec 2009.
Vousden KH (2009). Functions of p53 in metabolism and invasion. Biochem Soc Trans. 37, 511-7.
Vousden KH, Prives C (2009). Blinded by the Light: The Growing Complexity of p53. Cell 137, 413-31.
Vousden KH, Ryan KM (2009). p53 and metabolism. Nat Rev Cancer 9, 691-700.
2008
Carter S, Vousden KH (2008). p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 7, 2519-28.
Horn HF, Vousden KH (2008). Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 27, 5774-84.
Yee KS, Vousden KH (2008). Contribution of membrane localization to the apoptotic activity of PUMA. Apoptosis 13, 87-95.
Carter S, Vousden KH (2008). A role for Numb in p53 stabilization. Genome Biology 9, 221.
2007
Carter S, Bischof O, Dejean, Vousden KH. (2007). C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biology 9, 428-435.
Lukashchuk N, Vousden KH (2007). Ubiquitination and degradation of mutant p53. Mol Cell Biol. 27, 8284-95.
Uldrijan S, Pannekoek WJ, Vousden KH. (2007). An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO Journal 26, 102-112.
Bell HS, Dufes C, O’Prey J, Crighton D, Bergamaschi D, Lu X, Schatzlein AG, Vousden KH and Ryan KM (2007). A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest. 117, 1008-18.
Vikhanskaya F, Toh WH, Dulloo I, Wu Q, Boominatahn L, Ng HH, Vousden KH, Sabapathy K (2007). p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nat Cell Biol. 9, 698-706.
Wilson JM, Henderson G, Black F, Sutherland A, Ludwig RL, Vousden KH, Robins DJ. (2007). Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells. Bioorganic & Medicinal Chemistry 15, 77-86.
Yang Y, Kitagaki J, Dai R-M, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li C-CH, Kenten JH, Beutler JA, Vousden KH, Weissman AM (2007). Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67, 9472-81.
Bensaad K, Vousden KH (2007). p53: new roles in metabolism. Trends Cell Biol. 17, 286-91.
Horn HF, Vousden KH (2007). Coping with stress: multiple ways to activate p53. Oncogene 26, 1306-16.
Meier P, Vousden KH (2007). Lucifer’s labyrinth – ten years of path finding in cell death. Mol Cell. 28, 746-54.
Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol. 8, 275-83.
The p53 protein plays an important role in protecting from cancer. In part, this reflects its ability to inhibit proliferation or eliminate cells that have the potential for malignant progression but more recently, we have found that p53 can also contribute to protecting cells from DNA damage. 
